A Conditional Zebrafish MITF Mutation Reveals MITF Levels Are Critical for Melanoma Promotion vs. Regression In Vivo
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The microphthalmia-associated transcription factor (MITF) is the "master melanocyte transcription factor" with a complex role in melanoma. MITF protein levels vary between and within clinical specimens, and amplifications and gain- and loss-of-function mutations have been identified in melanoma. How MITF functions in melanoma development and the effects of targeting MITF in vivo are unknown because MITF levels have not been directly tested in a genetic animal model. Here, we use a temperature-sensitive mitf zebrafish mutant to conditionally control endogenous MITF activity. We show that low levels of endogenous MITF activity are oncogenic with BRAF(V600E) to promote melanoma that reflects the pathology of the human disease. Remarkably, abrogating MITF activity in BRAF(V600E)mitf melanoma leads to dramatic tumor regression marked by melanophage infiltration and increased apoptosis. These studies are significant because they show that targeting MITF activity is a potent antitumor mechanism, but also show that caution is required because low levels of wild-type MITF activity are oncogenic.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garraway, L. A., Widlund, H. R., Rubin, M. A., Getz, G., Berger, A. J., Ramaswamy, S., Beroukhim, R., Milner, D. A., Granter, S. R., Du, J., et al. (2005) · Nature · doi:10.1038/nature03664 · Cited by 1,548 · cited 6×
“This is in apparent contrast to evidence that MITF amplification is also an indicator of poor prognosis, and that MITF cooperates with BRAF to transform melanocytes (Garraway et al., 2005).”
BackgroundResultInfluentialMelanoma biology and new targeted therapy
Gray-Schopfer, V., Wellbrock, C., & Marais, R. (2007) · Nature · doi:10.1038/nature05661 · Cited by 1,371 · cited 2×
“Thus, a common feature of melanoma may involve maintaining sufficient MITF activity for survival and proliferation while at the same time restricting higher levels of MITF activity that promote cell cycle arrest and differentiation or lower levels that lead to cell cycle arrest and apoptosis (Gray-Schopfer et al., 200…”
BackgroundMITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169 · cited 3×
“The BRAFV600Emitf model is relevant to human melanoma, because for some patients, low expression of MITF is associated with disease progression and poor prognosis (Salti et al., 2000; Levy et al., 2006).”
BackgroundLister, J. A., Robertson, C. P., Lepage, T., Johnson, S. L., & Raible, D. W. (1999) · Development · doi:10.1242/dev.126.17.3757 · Cited by 819
Self-citationThe histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset
Ceol, C. J., Houvras, Y., Jane-Valbuena, J., Bilodeau, S., Orlando, D. A., Battisti, V., Fritsch, L., Lin, W. M., Hollmann, T. J., Ferré, F., et al. (2011) · Nature · doi:10.1038/nature09806 · Cited by 542 · cited 2×
“…mitfavc7 (Figure 1a–d; Johnson et al., 2011; originally characterized as fh53) and a transgenic line expressing BRAFV600E in melanocytes that we have previously developed and has been effective in the identification of cooperating driver genes (Figure 1e) (Patton et al., 2005; Ceol et al., 2011).”
BackgroundMelanoma: from mutations to medicine
Tsao, H., Chin, L., Garraway, L. A., & Fisher, D. E. (2012) · Genes & Development · doi:10.1101/gad.191999.112 · Cited by 496 · cited 3×
“Accumulating evidence indicates that MITF activity is a key contributing factor in melanoma (Tsao et al., 2012).”
BackgroundInterferon-γ links ultraviolet radiation to melanomagenesis in mice
Zaidi, M. R., Davis, S., Noonan, F. P., Graff-Cherry, C., Hawley, T. S., Walker, R. L., Feigenbaum, L., Fuchs, E., Lyakh, L., Young, H. A., et al. (2011) · Nature · doi:10.1038/nature09666 · Cited by 293 · cited 1×
“…participating in melanoma regression and/or clearance (Figure 5), we do not know their function in melanoma growth (Figure 2a): macrophages can lead to both melanoma regression (Nakashima et al., 2012) and promotion (Zaidi et al., 2011), or form melanoma–macrophage hybrids (Pawelek, 2007).”
BackgroundStrub, T., Giuliano, S., Ye, T., Bonet, C., Keime, C., Kobi, D., Le Gras, S., Cormont, M., Ballotti, R., Bertolotto, C., et al. (2011) · Oncogene · doi:10.1038/onc.2010.612 · Cited by 269 · cited 4×
“MITF activity can also vary within an individual melanoma, such that low levels of MITF promote invasion and stem-cell like phenotypes and moderate levels of MITF activity promote cell cycle progression (Goodall et al., 2008; Hoek and Goding, 2010; Cheli et al., 2011; Strub et al., 2011; Cheli et al., 2012).”
BackgroundInfluentialElevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation
Wellbrock, C., & Marais, R. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200505059 · Cited by 196 · cited 2×
“In these contexts, exogenous expression of MITF leads to inhibition of proliferation (Selzer et al., 2002; Wellbrock and Marais, 2005).”
BackgroundHypoxia and MITF control metastatic behaviour in mouse and human melanoma cells
Cheli, Y., Giuliano, S., Fenouille, N., Allegra, M., Hofman, V, Hofman, P., Bahadoran, P., Lacour, J.-P., Tartare-Deckert, S., Bertolotto, C., et al. (2012) · Oncogene · doi:10.1038/onc.2011.425 · Cited by 185
Cited by
The melanocyte lineage in development and disease
Mort, R. L., Jackson, I. J., & Patton, E. E. (2015) · Development · doi:10.1242/dev.106567 · Cited by 416
“Sox10 haploinsufficiency in mice can lead to tumour regression in an already established nevus, and in zebrafish, turning off MITF activity in an established melanoma leads to rapid tumour regression (Lister et al., 2014; Shakhova et al., 2012).”
BackgroundSelf-citationThe dynamic control of signal transduction networks in cancer cells
Kolch, W., Halasz, M., Granovskaya, M., & Kholodenko, B. N. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3983 · Cited by 339
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities
Rambow, F., Marine, J.-C., & Goding, C. R. (2019) · Genes & Development · doi:10.1101/gad.329771.119 · Cited by 325
MITF in melanoma: mechanisms behind its expression and activity
Hartman, M. L., & Czyz, M. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1791-0 · Cited by 320
In situ differentiation of iridophore crystallotypes underlies zebrafish stripe patterning
Gur, D., Bain, E. J., Johnson, K. R., Aman, A. J., Pasolli, H. A., Flynn, J. D., Allen, M. C., Deheyn, D. D., Lee, J. C., Lippincott-Schwartz, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20088-1 · Cited by 69
Melanocyte lineage dynamics in development, growth and disease
Brombin, A., & Patton, E. E. (2024) · Development · doi:10.1242/dev.201266 · Cited by 36
Self-citation
Metadata
- Authors
- Lister, J. A., Capper, A., Zeng, Z., Mathers, M. E., Richardson, J., Paranthaman, K., Jackson, I. J., & Elizabeth Patton, E.
- Venue
- Journal of Investigative Dermatology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 134
- Issue
- 1
- Pages
- 133-140
- ISSN
- 0022-202X (ISSN-L)
- OpenAlex
- W2094307203
- Cited by
- 98
- References
- 12
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.